Long-Term Survival of Methotrexate as First-Line Therapy in Rheumatoid Arthritis, Psoriatic Arthritis and Undifferentiated Arthritis
Fabio Massimo Perrotta, Pasquale Ambrosino, Ennio Lubrano · 2024
Read Long-Term Survival of Methotrexate as First-Line Therapy in Rheumatoid Arthritis, Psoriatic Arthritis and Undifferentiated Arthritis by Fabio Massimo Perrotta, Pasquale Ambrosino, Ennio Lubrano (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11727825.txt.
Description
Fabio Massimo Perrotta, Pasquale Ambrosino, and Ennio Lubrano track how long a first-line joint drug lasts in a 2024 study. In the age of bio drugs, the old drug still fronts care for three joint ills. The team asks how long new patients stay on it as their first pick.
Ward lists from a joint clinic span eight years of new starts with the drug. Curve maths reads the stay span for the group as a whole. Traits such as side ills and add-on drugs were logged for the checks.
Catalog record
| CREATOR | Fabio Massimo Perrotta, Pasquale Ambrosino, Ennio Lubrano |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |